David Christopher Metzger

Suggest Changes
Learn More
BACKGROUND Inhibition of the P2Y12 ADP-receptor with oral antiplatelet agents given to patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction(More)
  • 1